Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/105789
DC Field | Value | Language |
---|---|---|
dc.contributor | Department of Applied Biology and Chemical Technology | - |
dc.creator | Yu, C | - |
dc.creator | Wang, S | - |
dc.creator | Lai, WF | - |
dc.creator | Zhang, D | - |
dc.date.accessioned | 2024-04-23T04:31:19Z | - |
dc.date.available | 2024-04-23T04:31:19Z | - |
dc.identifier.uri | http://hdl.handle.net/10397/105789 | - |
dc.language.iso | en | en_US |
dc.publisher | MDPI AG | en_US |
dc.rights | Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). | en_US |
dc.rights | The following publication Yu C, Wang S, Lai W-F, Zhang D. The Progress of Chitosan-Based Nanoparticles for Intravesical Bladder Cancer Treatment. Pharmaceutics. 2023; 15(1):211 is available at https://doi.org/10.3390/pharmaceutics15010211. | en_US |
dc.subject | Bladder cancer | en_US |
dc.subject | Chitosan | en_US |
dc.subject | Intravesical drug delivery | en_US |
dc.subject | Nanoparticle | en_US |
dc.title | The progress of chitosan-based nanoparticles for intravesical bladder cancer treatment | en_US |
dc.type | Journal/Magazine Article | en_US |
dc.identifier.volume | 15 | - |
dc.identifier.issue | 1 | - |
dc.identifier.doi | 10.3390/pharmaceutics15010211 | - |
dcterms.abstract | Bladder cancer (BC) is the most frequently occurring cancer of the urinary system, with non-muscle-invasive bladder cancer (NMIBC) accounting for 75–85% of all the bladder cancers. Patients with NMIBC have a good survival rate but are at high risk for tumor recurrence and disease progression. Intravesical instillation of antitumor agents is the standard treatment for NMIBC following transurethral resection of bladder tumors. Chemotherapeutic drugs are broadly employed for bladder cancer treatment, but have limited efficacy due to chemo-resistance and systemic toxicity. Additionally, the periodic voiding of bladder and low permeability of the bladder urothelium impair the retention of drugs, resulting in a weak antitumoral response. Chitosan is a non-toxic and biocompatible polymer which enables better penetration of specific drugs to the deeper cell layers of the bladder as a consequence of temporarily abolishing the barrier function of urothelium, thus offering multifaceted biomedical applications in urinary bladder epithelial. Nowadays, the rapid development of nanoparticles significantly improves the tumor therapy with enhanced drug transport. This review presents an overview on the state of chitosan-based nanoparticles in the field of intravesical bladder cancer treatment. | - |
dcterms.accessRights | open access | en_US |
dcterms.bibliographicCitation | Pharmaceutics, Jan. 2023, v. 15, no. 1, 211 | - |
dcterms.isPartOf | Pharmaceutics | - |
dcterms.issued | 2023-01 | - |
dc.identifier.scopus | 2-s2.0-85146535449 | - |
dc.identifier.eissn | 1999-4923 | - |
dc.identifier.artn | 211 | - |
dc.description.validate | 202404 bcch | - |
dc.description.oa | Version of Record | en_US |
dc.identifier.FolderNumber | OA_Scopus/WOS | en_US |
dc.description.fundingSource | Self-funded | en_US |
dc.description.pubStatus | Published | en_US |
dc.description.oaCategory | CC | en_US |
Appears in Collections: | Journal/Magazine Article |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
pharmaceutics-15-00211.pdf | 947.03 kB | Adobe PDF | View/Open |
Page views
10
Citations as of Jun 30, 2024
Downloads
2
Citations as of Jun 30, 2024
SCOPUSTM
Citations
5
Citations as of Jul 4, 2024
WEB OF SCIENCETM
Citations
4
Citations as of Jul 4, 2024
![](/image/google_scholar.jpg)
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.